文献速递消化系统肿瘤

应对claudin阳性晚期胃癌患者中佐妥昔单抗的临床挑战

Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer.
PubMed 文献 · Eur J Cancer · 2025-05-29

佐妥昔单抗联合化疗在HER2阴性、CLDN18.2阳性晚期胃/胃食管结合部腺癌中显示生存获益,但临床整合面临PD-L1共表达时治疗选择及恶心呕吐管理两大挑战。本综述基于随机对照试验、监管批准和专家共识,提出PD-L1 CPS≥10可作为倾向免疫检查点抑制剂方案的实用决策阈值,并强调首周期需优化止吐策略和控制输注速度。

要点

  • CLDN18.2阳性/PD-L1阳性患者中,PD-L1 CPS高者免疫检查点抑制剂可能长期生存获益更大,CPS阴性至低表达或ICI禁忌者佐妥昔单抗可能更优。
  • 佐妥昔单抗相关恶心呕吐见于超过四分之三患者,首次输注时因负荷剂量和较快输注速度而更频繁严重。
  • 作者主张以PD-L1 CPS≥10作为倾向ICI方案的实用决策阈值,并建议优化预防性和治疗中止吐策略以提高依从性。

核心结论

  • 在CLDN18.2阳性/PD-L1阳性患者中,PD-L1 CPS高时ICI可能提供更大长期生存获益,而CPS阴性至低表达或ICI禁忌时佐妥昔单抗可能更优。
  • 作者主张PD-L1 CPS≥10作为倾向ICI方案的实用决策阈值,但治疗选择应基于合并症、全面分子特征和可用后续方案个体化。
  • 作者建议优化预防性和治疗中止吐策略对提高佐妥昔单抗依从性和最大化临床结局至关重要。

研究设计与样本

  • 本综述批判性回顾了随机对照试验、监管批准和近期关于佐妥昔单抗管理的专家共识证据。

主要发现

  • 佐妥昔单抗联合化疗在HER2阴性、CLDN18.2阳性晚期胃/胃食管结合部腺癌中显示显著生存获益。
  • 恶心呕吐见于超过四分之三的患者,首次输注时因负荷剂量和较快输注速度而更频繁且严重。

关键数值与推荐

  • 在CLDN18.2和PD-L1 CPS共阳性时,作者主张以PD-L1 CPS≥10作为倾向ICI方案的实用决策阈值。
  • 恶心呕吐管理包括严格遵循高风险止吐方案(含NK-1/5-HT3拮抗剂和皮质类固醇)以及通过停走策略仔细控制输注速度。

临床怎么用

  • 作者建议优化预防性和治疗中止吐策略以提高佐妥昔单抗依从性和最大化临床结局。
  • 作者主张在CLDN18.2和PD-L1 CPS共阳性时以PD-L1 CPS≥10作为倾向ICI方案的实用决策阈值。
  • 治疗选择应基于合并症、全面分子特征和可用后续方案个体化。
  • 首周期需特别注意,因输注相关恶心呕吐风险较高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zolbetuximab, a first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN 18.2), has demonstrated significant survival benefit when combined with chemotherapy in HER2-negative, CLDN 18.2-positive advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. However, its integration into clinical practice presents two major challenges: the best treatment selection between zolbetuximab or immune checkpoint inhibitor (ICI)-based regimens in patients co-expressing programmed death-ligand 1 (PD-L1), and the management of zolbetuximab-related nausea and vomiting (N/V). We critically reviewed evidence from randomized controlled trials, regulatory approvals, and recent expert consensus on zolbetuximab management. In CLDN 18.2-positive/PD-L1-positive patients, ICIs may offer greater long-term survival benefit especially in case of high PD-L1 CPS, while zolbetuximab may be preferred in patients with negative-to-low CPS or ICIs contraindications. N/V, reported in more than three-quarter of patients, is more frequent and severe during the first infusion, due to zolbetuximab loading dose and faster infusion rate. Proper management includes accurate adherence to high-risk antiemetic protocols (including NK-1/5-HT3 antagonists and corticosteroids) and careful control of infusion rates with a stop and go strategy. In case of CLDN 18.2 and PD-L1 CPS co-positivity, we advocate the use of PD-L1 CPS ≥ 10 as a practical decision-making threshold for favoring ICI-based regimens. However, the treatment selection should be tailored on comorbidities, comprehensive molecular characterization and available subsequent options. To ensure the optimal use of zolbetuximab, special attention is required during the first cycle, due to higher risk of infusion-related N/V. We suggest that the optimization of both prophylactic and on-treatment antiemetic strategies is essential to enhance zolbetuximab adherence and maximize clinical outcomes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rosanu NM, Gervaso L, Cella CA, et al. Navigating the clinical challenges of zolbetuximab in patients with claudin positive advanced gastric cancer. Eur J Cancer. 2025. PMID: 40466467. doi:10.1016/j.ejca.2025.115521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。